Polygenes, risk prediction, and targeted prevention of breast cancer.

BACKGROUND New developments in the search for susceptibility alleles in complex disorders provide support for the possibility of a polygenic approach to the prevention and treatment of common diseases. METHODS We examined the implications, both for individualized disease prevention and for public health policy, of findings concerning the risk of breast cancer that are based on common genetic variation. RESULTS Our analysis suggests that the risk profile generated by the known, common, moderate-risk alleles does not provide sufficient discrimination to warrant individualized prevention. However, useful risk stratification may be possible in the context of programs for disease prevention in the general population. CONCLUSIONS The clinical use of single, common, low-penetrance genes is limited, but a few susceptibility alleles may distinguish women who are at high risk for breast cancer from those who are at low risk, particularly in the context of population screening.

[1]  S. Friend.  Breast cancer susceptibility testing: realities in the post–genomic era , 1996, Nature Genetics.

[2]  N. Day,et al.  Family history and the risk of breast cancer: A systematic review and meta‐analysis , 1997, International journal of cancer.

[3]  U. Werneke.  Ataxia telangiectasia and risk of breast cancer , 1997, The Lancet.

[4]  M. Swift.  Ataxia telangiectasia and risk of breast cancer , 1997, The Lancet.

[5]  P. Pharoah,et al.  Absolute risk of breast cancer in women at increased risk: a more useful clinical measure than relative risk? , 1998 .

[6]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[7]  C. Rotimi,et al.  Hypertension treatment and control in sub-Saharan Africa: the epidemiological basis for policy , 1998, BMJ.

[8]  D. Easton.  How many more breast cancer predisposition genes are there? , 1999, Breast Cancer Research.

[9]  A. Beaudet.  1998 ASHG presidential address. Making genomic medicine a reality. , 1999, American journal of human genetics.

[10]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[11]  A. Beaudet.  Making Genomic Medicine a Reality , 1999 .

[12]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[13]  N. Holtzman,et al.  Will genetics revolutionize medicine? , 2000, The New England journal of medicine.

[14]  J. Peto,et al.  High constant incidence in twins and other relatives of women with breast cancer , 2000, Nature Genetics.

[15]  R. Goldbohm,et al.  Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease , 2001, The Lancet.

[16]  P. Vineis,et al.  Misconceptions about the use of genetic tests in populations , 2001, The Lancet.

[17]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[18]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[19]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[20]  The Polish Breast Cancer Consortium.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .

[21]  Douglas F. Easton,et al.  Association studies for finding cancer-susceptibility genetic variants , 2004, Nature Reviews Cancer.

[22]  D. Gudbjartsson,et al.  Cancer as a Complex Phenotype: Pattern of Cancer Distribution within and beyond the Nuclear Family , 2004, PLoS medicine.

[23]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.

[24]  D. Easton,et al.  BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families , 2005, Breast Cancer Research.

[25]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[26]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[27]  Jaana M. Hartikainen,et al.  A common coding variant in CASP8 is associated with breast cancer risk , 2007, Nature Genetics.

[28]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[29]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[30]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[31]  D. Gudbjartsson,et al.  Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer , 2007, Nature Genetics.

[32]  A. Sigurdsson,et al.  Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer , 2008, Nature Genetics.

[33]  J. Brooks.  Why most published research findings are false: Ioannidis JP, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece , 2008 .